Wave Life Sciences. has filed a patent for oligonucleotides, compositions, and methods for preventing and treating various conditions, disorders, or diseases. The technologies involve modifications to nucleobases, sugars, and internucleotidic linkages, and specifically target the MAPT gene. The patent claims an oligonucleotide with a base sequence that is identical or complementary to a MAPT gene sequence, containing modified sugars, nucleobases, and/or internucleotidic linkages. GlobalData’s report on Wave Life Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Wave Life Sciences, siRNA gene silencing was a key innovation area identified from patents. Wave Life Sciences's grant share as of September 2023 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
A recently filed patent (Publication Number: US20230295619A1) describes an oligonucleotide that can target and reduce the level, expression, and activity of a MAPT gene or transcript. The oligonucleotide consists of a base sequence that is identical or complementary to a MAPT gene or transcript, and it contains modified sugars, nucleobases, and internucleotidic linkages. The patent claims cover various aspects of the oligonucleotide, including its base sequence length, specific sequences, sugar modifications, and backbone chiral centers.
The patent also describes a pharmaceutical composition that includes the oligonucleotide and a pharmaceutically acceptable carrier. The composition can be in the form of an aqueous solution containing dissolved salt forms of the oligonucleotide. Additionally, the patent claims cover oligonucleotide compositions that consist of multiple oligonucleotides sharing a common base sequence and the same chiral internucleotidic linkages. These compositions can be enriched for specific oligonucleotide types and are capable of reducing the level, expression, and activity of a MAPT transcript.
Methods for preparing the oligonucleotide and compositions are also described in the patent. These methods involve the use of chiral auxiliaries, such as DPSE and PSM, to control the stereochemistry of the internucleotidic linkages. The patent further discloses methods for reducing the level, function, and activity of a tau protein, as well as methods for treating or preventing MAPT-related conditions, neurodegenerative diseases, and tauopathies in subjects.
Overall, the patent presents a novel oligonucleotide and its various compositions and methods for targeting and reducing the expression of a MAPT gene or transcript. The oligonucleotide has potential applications in the treatment and prevention of MAPT-related conditions and neurodegenerative diseases.
To know more about GlobalData’s detailed insights on Wave Life Sciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
